Page 75 - GTM-3-2

Global Translational Medicine Genes and blood cells in Ph-negative MPNs

21. Gadomska G, Rość D, Stankowska K, Boinska J, Ruszkowska- doi: 10.1182/asheducation-2007.1.363
Ciastek B, Wieczór R. Selected parameters of hemostasis in 32. Birdane A, Haznedaroğlu IC, Bavbek N, et al. The plasma
patients with myeloproliferative neoplasms. Blood Coagul levels of prostanoids and plasminogen activator inhibitor-1
Fibrinolysis. 2014;25(5):464-470. in primary and secondary thrombocytosis. Clin Appl
doi: 10.1097/MBC.0000000000000088 Thromb Hemost. 2005;11(2):197-201.
22. Swerdlow SH, Campo E, Harris NL, et al., editors. WHO doi: 10.1177/107602960501100209
Classification of Tumours of Haematopoietic and Lymphoid 33. Brogren H, Wallmark K, Deinum J, Karlsson L, Jern S.
Tissues. Lyon: International Agency for Research on Cancer; Platelets retain high levels of active plasminogen activator
2017. inhibitor 1. PLoS One. 2011;6(11):e26762.
23. Van Egeren D, Kamaz B, Liu S, et al. Transcriptional doi: 10.1371/journal.pone.0026762
differences between JAK2-V617F and wild-type bone
marrow cells in patients with myeloproliferative neoplasms. 34. Corduan A, Plé H, Laffont B, et al. Dissociation of
Exp Hematol. 2022;107:14-19. SERPINE1 mRNA from the translational repressor proteins
Ago2 and TIA-1 upon platelet activation. Thromb Haemost.
doi: 10.1016/j.exphem.2021.12.364 2015;113(5):1046-1059.
24. Makukh HV, Chorna LB, Hnateyko OZ, Zastavna DV. doi: 10.1160/TH14-07-0622
Molecular genetic diagnosis of hereditary factors of 35. Bazzan M, Tamponi G, Gallo E, et al. Fibrinolytic imbalance
thrombophilia: mutations g1691a of the FV gene and in essential thrombocythemia: Role of platelets. Haemostasis.
g20210a of the FII gene, allelic polymorphism 675 4g/5g 1993;23(1):38-44.
of the PAI-1 gene. Lab Diagn. 2012;1(59):32-37. (Article in
Ukrainian) doi: 10.1159/000216850
25. Kubala MH, DeClerck YA. The plasminogen activator 36. Robbie LA, Bennett B, Croll AM, Brown PA, Booth NA.
inhibitor-1 paradox in cancer: A mechanistic understanding. Proteins of the fibrinolytic system in human thrombi.
Cancer Metastasis Rev. 2019;38(3):483-492. Thromb Haemost. 1996;75(1):127-133.
doi: 10.1007/s10555-019-09806-4 37. Colucci M, Semeraro N, Semeraro F. Platelets and
fibrinolysis. In: Gresele P, Kleiman N, Lopez J, Page C,
26. Wang J, Peng Y, Guo H, Li C. PAI-1 polymorphisms editors. Platelets in Thrombotic and Non-Thrombotic
have significant associations with cancer risk, Disorders. Cham, Switzerland: Springer; 2017.
especially feminine cancer. Technol Cancer Res Treat.
2021;20:15330338211037813. 38. Zhu Y, Carmeliet P, Fay WP. Plasminogen activator
inhibitor-1 is a major determinant of arterial thrombolysis
doi: 10.1177/15330338211037813 resistance. Circulation. 1999;99(23):3050-3055.
27. Vassalli LC, Malafaia EC, Chauffaille ML, Kerbauy D. doi: 10.1161/01.cir.99.23.3050
Leukocytosis can predict thrombotic events in myelofibrosis. 39. Gieger C, Radhakrishnan A, Cvejic A, et al. New gene
Blood. 2015;126(23):5191.
functions in megakaryopoiesis and platelet formation.
doi: 10.1182/blood.v126.23.5191.5191 Nature. 2011;480(7376):201-208.
28. Ohyashiki K, Kiguchi T, Ito Y, et al. Leukocytosis is linked doi: 10.1038/nature10659
to thrombosis at diagnosis, while JAK2 V617F mutation is 40. Soranzo N, Rendon A, Gieger C, et al. A novel variant on
associated with thrombosis during the course of essential chromosome 7q22.3 associated with mean platelet volume,
thrombocythemia. Int J Hematol. 2008;87:446-448. counts, and function. Blood. 2009;113(16):3831-3837.
doi: 10.1007/s12185-008-0080-9 doi: 10.1182/blood-2008-10-184234
29. Cerutti A, Custodi P, Duranti M, Noris P, Balduini CL. 41. Cotter FE, Johnson E. Chromosome 7 and haematological
Thrombopoietin levels in patients with primary and reactive malignancies. Hematology. 1997;2(5):359-372.
thrombocytosis. Br J Haematol. 1997;99(2):281-284.
doi: 10.1080/10245332.1997.11746356
doi: 10.1046/j.1365-2141.1997.3823196.x
42. Viny AD, Przychodzen B, O’Keefe CL et al. Various
30. Koupenova M, Clancy L, Corkrey HA, Freedman JE. abnormalities at chromosome 7 carry distinct biologic
Circulating platelets as mediators of immunity, inflammation, and prognostic implications in myelodysplastic/
and thrombosis. Circ Res. 2018;122(2):337-351. myeloproliferative syndromes and related marrow failures.
Blood. 2010;116(21):2744-2744.
doi: 10.1161/CIRCRESAHA.117.310795
doi: 10.1182/blood.v116.21.2744.2744
31. Vannucchi AM, Barbui T. Thrombocytosis and thrombosis.
Hematology. 2007;1:363-370. 43. Piguet PF, Vesin C, Da Laperousaz C, Rochat A. Role of

Volume 3 Issue 2 (2024) 11 doi: 10.36922/gtm.2559